What's Wrong With Vertex Pharmaceuticals Stock?
Vertex Pharmaceuticals (NASDAQ: VRTX) has been a top pharma stock in recent years. It has been generating strong revenue growth while also building out its portfolio of drugs, expanding its growth opportunities in the process. This is the type of stock that you might expect to see taking off this year.
But that isn't happening.
Instead, the share price of Vertex recently plunged. Excitement around the company has cooled drastically. What's wrong with Vertex Pharmaceuticals, and is it an investment worth buying on the dip, or could there be more trouble ahead for the healthcare stock?
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
374,90 €
1,49 %
Einseitige Meinung: Vertex Pharmaceuticals Inc. erhält nur Buy-Einschätzungen und keine Sell-Einschätzungen.
Das von der Community festgelegte Kursziel von 461 € für Vertex Pharmaceuticals Inc. bedeutet eine mögliche Steigerung um über 20% im Vergleich zu 374.9 €.
